Document is current
Any future updates will be listed below
-
Authors
Aoyama, Taro
Kakizaki, Fumihiko
Miyoshi, Hiroyuki
Sonoshita, Masahiro
Maekawa, Hisatsugu
Itatani, Yoshiro
Kawada, Kenji
Matsusue, Ryo
Ikai, Iwao
Moriyoshi, Koki
Sakurai, Takaki
Obama, Kazutaka
Sato, Tosiya Shun
Sakai, Yoshiharu
Taketo, Makoto Mark
-
Funding
Funding for this research was provided by:
Japan Science and Technology Agency (ST261001TT)
Japan Agency for Medical Research and Development (ck0106195h)
- License Information
-
More Information
Article History
Received: 20 August 2024
Revised: 14 May 2025
Accepted: 21 June 2025
First Online: 25 July 2025
Competing interests
: MMT has ownership interest in and consultant/advisory board relationship with KyoDiagnostics KK (Kyoto, Japan) that executes patent rights owned by Kyoto University for diagnostic use of TRIO pY2681 antibodies. Other authors have no competing interests.
: This study was performed in accordance with the Declaration of Helsinki. The study protocol involving human samples was approved by the Kyoto University Graduate School and Faculty of Medicine, Ethics Committee as well as the Ethics Committee of Kyoto Medical Center. All participants provided their written informed consent for study participation, including the use of their tissue samples and data analysis (Approval No. G0550, FY 2013-2024).
